Launch coincides with the Healthcare 2030 Summit in Washington, DC, bringing together top government officials, industry leaders, and patient advocates…
In this free webinar, gain insight into the current landscape of "Bring Your Own Device" (BYOD) adoption across therapeutic areas…
In this free webinar, gain insight into patterns in the current use of clinical outcome assessment (COA) and digital health…
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with…
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of…
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)…
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner Dr. Turner…
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based…
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which…
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key…